

Accepted Manuscript

Lipophilic nalmefene prodrugs to achieve a one-month sustained release

Tim Gaekens, Michel Guillaume, Herman Borghys, Loeckie L. De Zwart, Ronald de Vries, Roger C.A. Embrechts, An Vermeulen, Anton A.H.P. Megens, Josée E. Leysen, Piet Herdewijn, Pieter P. Annaert, John R. Atack

PII: S0168-3659(16)30242-5
DOI: doi: [10.1016/j.jconrel.2016.04.029](https://doi.org/10.1016/j.jconrel.2016.04.029)
Reference: COREL 8232

To appear in: *Journal of Controlled Release*

Received date: 17 December 2015
Revised date: 18 April 2016
Accepted date: 18 April 2016



Please cite this article as: Tim Gaekens, Michel Guillaume, Herman Borghys, Loeckie L. De Zwart, Ronald de Vries, Roger C.A. Embrechts, An Vermeulen, Anton A.H.P. Megens, Josée E. Leysen, Piet Herdewijn, Pieter P. Annaert, John R. Atack, Lipophilic nalmefene prodrugs to achieve a one-month sustained release, *Journal of Controlled Release* (2016), doi: [10.1016/j.jconrel.2016.04.029](https://doi.org/10.1016/j.jconrel.2016.04.029)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Lipophilic Nalmefene Prodrugs to Achieve a One-Month Sustained Release

Tim Gaekens^a, Michel Guillaume^a, Herman Borghys^b, Loeckie L. De Zwart^c, Ronald de Vries^c, Roger C.A. Embrechts^d, An Vermeulen^e, Anton A.H.P. Megens^b, Josée E. Leysen^{b,f}, Piet Herdewijn^g, Pieter P. Annaert^h and John R. Atack^{b,*}

^a API Small Molecule Development, Janssen Pharmaceuticals, Turnhoutseweg 30, B-2340 Beerse, Belgium

^b Neuroscience, Janssen Pharmaceuticals, Turnhoutseweg 30, B-2340 Beerse, Belgium

^c Drug Metabolism and Pharmacokinetics, Janssen Pharmaceuticals, Turnhoutseweg 30, B-2340 Beerse, Belgium

^d Drug Product Development, Janssen Pharmaceuticals, Turnhoutseweg 30, B-2340 Beerse, Belgium

^e Clinical Pharmacology, Janssen Pharmaceuticals, Turnhoutseweg 30, B-2340 Beerse, Belgium

^f Department of Nuclear Medicine and PET Research, VU University Medical Centre, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands

^g Laboratory of Medicinal Chemistry, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, Box 1030, B-3000 Leuven, Belgium

^h Laboratory for Pharmacotechnology and Biopharmacy, Katholieke Universiteit Leuven, O&N2, Herestraat 49-Box 921, B-3000 Leuven, Belgium

* Address correspondence, proofs and reprint requests to Prof. John R. Atack at his current address:

Sussex Drug Discovery Centre

School of Life Sciences

Room 2R314B, Chichester II

University of Sussex

Brighton, BN1 9QJ

United Kingdom

Tel: +44-(0)1273-872722

E-mail: J.Ataack@Sussex.ac.uk

Download English Version:

<https://daneshyari.com/en/article/7861825>

Download Persian Version:

<https://daneshyari.com/article/7861825>

[Daneshyari.com](https://daneshyari.com)